Develops sonelokimab, an experimental treatment for inflammatory skin and joint diseases, for patients with conditions such as hidradenitis suppurativa and psoriatic arthritis.
10-K for FY2025, filed Feb 25, 2026
10-Q for Q3 FY2026, filed Nov 4, 2026
−$79.5MView ↗
Broader clinical focus
The earlier report described hidradenitis suppurativa and psoriatic arthritis as initial development targets; the latest report identifies axial spondyloarthritis and palmoplantar pustulosis as additional target diseases.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Feb 25, 2026We currently develop SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A…View ↗
Loading...